246 related articles for article (PubMed ID: 24336963)
1. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
[TBL] [Abstract][Full Text] [Related]
2. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
3. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Dixit A; Torkamani A; Schork NJ; Verkhivker G
Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
[TBL] [Abstract][Full Text] [Related]
4. Defects in the calcium-binding region drastically affect the cadherin-like domains of RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
Phys Chem Chem Phys; 2016 Mar; 18(12):8673-81. PubMed ID: 26950000
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain.
Chen YJ; Li PY; Yang CN
J Struct Biol; 2021 Dec; 213(4):107799. PubMed ID: 34563653
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
[TBL] [Abstract][Full Text] [Related]
9. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.
Cranston AN; Carniti C; Oakhill K; Radzio-Andzelm E; Stone EA; McCallion AS; Hodgson S; Clarke S; Mondellini P; Leyland J; Pierotti MA; Whittaker J; Taylor SS; Bongarzone I; Ponder BA
Cancer Res; 2006 Oct; 66(20):10179-87. PubMed ID: 17047083
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
11. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Gujral TS; Singh VK; Jia Z; Mulligan LM
Cancer Res; 2006 Nov; 66(22):10741-9. PubMed ID: 17108110
[TBL] [Abstract][Full Text] [Related]
13. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
14. Influence of V54M mutation in giant muscle protein titin: a computational screening and molecular dynamics approach.
Thirumal Kumar D; George Priya Doss C; Sneha P; Tayubi IA; Siva R; Chakraborty C; Magesh R
J Biomol Struct Dyn; 2017 Apr; 35(5):917-928. PubMed ID: 27125723
[TBL] [Abstract][Full Text] [Related]
15. Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease.
Hyndman BD; Gujral TS; Krieger JR; Cockburn JG; Mulligan LM
Hum Mutat; 2013 Jan; 34(1):132-42. PubMed ID: 22837065
[TBL] [Abstract][Full Text] [Related]
16. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
[TBL] [Abstract][Full Text] [Related]
17. Predicting the impact of deleterious mutations in the protein kinase domain of FGFR2 in the context of function, structure, and pathogenesis--a bioinformatics approach.
C GP; Rajith B; Chakraborty C
Appl Biochem Biotechnol; 2013 Aug; 170(8):1853-70. PubMed ID: 23754559
[TBL] [Abstract][Full Text] [Related]
18. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Gujral TS; Mulligan LM
Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Kumar DT; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
